Blue Jet Healthcare Limited
Momentum (86/100) does the heavy lifting; financial trend (0/100) is the drag.
Fair valueBlue Jet Healthcare Limited earns a Hold from StocksWizard, with a blended score of 51/100. We put fair value near ₹473.07; at ₹602.75 that leaves roughly 22% downside, so the stock screens overvalued by 22%. On 39.6x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. The price is about 25% below its 52-week high of ₹804.53 and 84% above the low of ₹327.25. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹501 implies about 17% downside across 5 analysts. It clears 8 of 13 investability checks, with durability 83, valuation 44 and momentum 86 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹378.45.
Analyst views
1-year price
EOD · 2026-07-2952-week range
-25.08% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold51Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 19.9%
- Pass: Low debt (D/E < 0.5): 0.03x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -31%
- Fail: Earnings growing: -42%
- Pass: Net margin ≥ 10%: 26.2%
- Pass: Current ratio > 1.5: 4.21
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 23.03
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter76.0%
- Institutions4.7%
- Public & other19.3%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (19.9%).
- Lightly leveraged balance sheet.
- Healthy profit margin (26.2%).
- Financially solid — Altman Z 23.03.
Bear case
Threats
- Earnings contracting year on year.
- Trades ~22% above our estimated fair value.
About Blue Jet Healthcare Limited
Blue Jet Healthcare manufactures and sells pharmaceutical intermediates and active pharmaceutical ingredients for the pharmaceutical and healthcare industries. Its offerings include contrast media intermediates, niche pharmaceutical intermediates and APIs, and contract development and manufacturing services. The company provides end-to-end solutions encompassing process development, commercialization of new chemical entities, advanced intermediates, APIs, and building blocks.
Blue Jet Healthcare Limited — frequently asked questions
Is Blue Jet Healthcare Limited a buy, hold or sell?
StocksWizard currently rates Blue Jet Healthcare Limited (BLUEJET) a Hold, based on a blended score of 51/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Blue Jet Healthcare Limited's fair value?
Our blended DCF and relative-valuation model estimates Blue Jet Healthcare Limited's fair value at about ₹473.07, versus a current price of ₹602.75 — roughly 22% downside. On that basis the stock looks overvalued by 22%.
Is Blue Jet Healthcare Limited financially healthy?
Blue Jet Healthcare Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Blue Jet Healthcare Limited's share price performed?
Blue Jet Healthcare Limited is up 36% over three months, and last traded at ₹602.75. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.